Clinical Trial Update: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing FOLFOX-4 with and without cetuximab in first-line metastatic colorectal cancer (RAS wild-type) completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• FOLFOX-4 (oxaliplatin, folinic acid, 5-fluorouracil) (oxaliplatin; folinic acid; 5-fluorouracil)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-03-06